NCT number |
Condition or disease |
The
device, frequency, intensity, and exposure time of TTFields |
Combining therapy |
status |
NCT02831959 |
Non-small cell lung cancer brain metastasis |
NovoTTF-200A; 150 kHz; >18 hours/day |
Stereotactic radio
surgery |
Recruiting |
NCT05341349 |
Melanoma brain metastases |
NovoTTF-100M; ≥8hours/day |
Ipilimumab, Nivolumab, Pembrolizumab, Stereotactic, Radiosurgery |
Not
yet recruiting |
NCT04967027
|
Brain metastasis with drug/radiation resistant
|
ASCLU-300 TTF;
≥18hours/day
|
-
|
Recruiting
|
NCT04221503 |
GBM |
Optune; ≥18hours/day |
Niraparib, Planned surgical
resection |
Recruiting |
NCT04689087 |
rGBM |
Not mentioned |
Second-line chemotherapy treatment |
Recruiting |
NCT04223999 |
First recurrence GBM |
≥18hours/day |
Skullremodeling
surgery |
Recruiting |
NCT04397679 |
ndGBM |
≥18hours/day |
Partial Brain radiotherapy,
Temozolomide, Chloroquine |
Recruiting |
NCT03405792 |
ndGBM |
Optune; 24months |
Temozolomide, Pembrolizumab |
Active, not recruiting |
NCT03223103 |
ndGBM |
Optune |
Poly-ICLC, Peptides |
Active, not
recruiting |
NCT04671459 |
GBM and rGBM |
Optune |
Stereotactic radiosurgery |
Recruiting |
NCT05030298 |
Malignant Glioma |
Not available |
RT, TMZ, radiosurgery |
Not yet recruiting |
NCT04902586 |
Glioma and GBM |
Low-intensity; 200 kHz; ≥18hours/day |
Radiotherapy |
Not yet recruiting |
NCT04396860 |
Gliosarcoma and MGMT-unmethylated GBM |
NovoTTF-100A |
Ipilimumab, Nivolumab |
Recruiting |
NCT03033992 |
Paediatric malignant glioma ependymoma |
NovoTTF-200A;
≥18hours/day |
- |
Recruiting |
NCT05086497 |
GBM |
Optune array layout mapping created from
conventional/advanced MR imaging sequences |
- |
Not yet
recruiting |